±èÈñÁø ¸íÀÇ

Ä¡¸ÅÀÇ ´Ù¾çÇÑ Æ¯¼º°ú Á¶±â Áø´Ü°ú Ä¡·á¿¡ Àû¿ëÇϱâ À§ÇÑ ¿©·¯ À¶ÇÕ ¿¬±¸µéÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

±èÈñÁø ¸íÀÇ

  • ¼Ò ¼Ó
    ÇѾç´ëÇб³º´¿ø
  • Áø·á°ú
    ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    Ä¡¸Å, ÀÎÁö±â´ÉÀúÇÏ

ÇѾç´ëÇб³º´¿ø ½Å°æ°ú¿¡¼­´Â Àü¹®È­µÈ Ä¡·áÁø°ú ¿¬±¸ÁøµéÀÌ Á¤È®ÇÑ Ä£´Ü ¹× ÃÖ÷´Ü Ä¡·á¸¦ À§ÇØ ±âÃÊÀÇÇÐ, ¿µ»óÀÇÇÐ, ÇÙÀÇÇаú¿Í ¿¬°èÇÏ¿© ȯÀÚÀÇ ÀüÀÎÀûÀÎ Ä¡·á¸¦ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. 2008³âºÎÅÍ ÇöÀç ±îÁö ¼ºµ¿±¸ Ä¡¸ÅÁö¿ø¼¾Å͸¦ Á÷Á¢ ¿î¿µÀ» ÅëÇÑ Ä¡¸Å ȯÀÚ Áø´Ü ¹× °ü¸®ÀÇ ³ëÇϿ츦 ÃàÀûÇÏ¿´°í, 2018³âºÎÅÍ º¸°Çº¹ÁöºÎ »êÇÏ Ä¡¸Å±Øº¹°úÁ¦¿Í ¹Ì·¡ºÎ »êÇÏ ³ú¿øÃµ °úÁ¦¸¦ ¼öÇàÇÏ¿©, °³ÀÎÇü, ¸ÂÃãÇü Ä¡¸Å Ä¡·á ¹× ¿øÀαԸíÀ» ½ÃÀÛÇÏ¿´½À´Ï´Ù. 2023³âºÎÅÍ ¿¬±¸Àç´Ü°ú ÇÔ²² ÀÎÁöÀúÇÏ À§Ç豺ÀÇ Àû±ØÀû °ü¸®¸¦ ÅëÇØ Ä¡¸Å ¿¹¹æ¿¡ ¾ÕÀå¼­°í ÀÖ½À´Ï´Ù. ÇѾç´ëÇб³º´¿ø ½Å°æ°úÀÇ Àû±ØÀûÀÎ Á¢±Ù°ú ¿¹¹æ, ºü¸¥ Ä¡·á°¡ ¿©·¯ºÐÀÇ ³ú°Ç°­À» ÁöÄѵ帮°Ú½À´Ï´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ÀÌÈ­¿©´ë ÀÇ´ë Çлç
  • ÀÌÈ­¿©´ë ÀÇ´ë ¼®»ç
  • ÀÌÈ­¿©´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼ºµ¿±¸Ä¡¸Å¾È½É¼¾ÅÍÀå
  • úÞ) ÇѾç´ëÇб³º´¿ø ±âȹÁ¶Á¤½ÇÀå
  • úÞ) ÇѾç´ëÇб³º´¿ø ½Å°æ°ú ±³¼ö
  • ÇѾç´ëÇб³ÀÇ·á¿ø ´ë¿ÜÇù·Â½ÇÀå
  • ÇѾç´ëÇб³º´¿ø ½Å°æ°ú °úÀå
  • ÇѾç´ëÇб³º´¿ø ½Å°æ°ú ÀÓ»ó±³¼ö
  • °Ç±¹´ëÇб³º´¿ø ½Å°æ°ú ÀÓ»ó±³¼ö

¼ö»ó³»¿ª

Awards List
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿ì¼öÆ÷½ºÅ͹ßÇ¥»ó (2020)
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿ì¼ö³í¹®»ó (2011)
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿ì¼ö³í¹®»ó (2010)
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿¡ÀÚÀÌÇмú»ó (2007)
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿ì¼ö³í¹®»ó (2005)

ÇÐȸȰµ¿

Academic activities
  • 2008 ~ ÇöÀç´ëÇѽŰæ°úÇÐȸ Çмú°£»ç, ÇмúÀ§¿ø
  • 2022 ~ ÇöÀç´ëÇѳëÀνŰæÀÇÇÐÈ£ È«º¸ÀÌ»ç
  • 2023 ~ ÇöÀç´ëÇѽŰæ°úÇÐȸ Á¤º¸ÀÌ»ç
  • 2024 ~ ÇöÀç´ëÇÑÄ¡¸ÅÇÐȸ À±¸®ÀÌ»ç
´À¸®°Ô ³ªÀ̵å´Â ±â¾ï·ÂÀÇ ºñ¹Ð
´ëÇ¥¼­Àû

´À¸®°Ô ³ªÀ̵å´Â ±â¾ï·ÂÀÇ ºñ¹Ð

  • ÀúÀÚ(±Û)±èÈñÁø
  • ÃâÆÇ»ç¾Þ±ÛºÏ½º
  • ¹ßÇàÀÏ2024³â 04¿ù 16ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 1°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Amyloid Burden in Alzheimer's Disease Patients Is Associated with Alterations in Circadian Rhythm.
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Dementia Neurocog Dis.
Á¦ ¸ñ Impact of an Education Program for Caregivers of Patients with Alzheimer¡¯s Disease on Treatment Discontinuation and Compliance in Korea.
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö J Clin Neurol
Á¦ ¸ñ Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Dementia Neurocog Dis.
Á¦ ¸ñ Prediction of Amyloid ¥â-Positivity with both MRI Parameters and Cognitive Function Using Machine Learning
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö The Korean Society of Radiology
Á¦ ¸ñ Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Journal of Cerebral Blood Flow & Metabolism
Á¦ ¸ñ A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer¡¯s Disease Already Receiving Donepezil (ROMEO-AD)
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Neurol Ther
Á¦ ¸ñ Impact of the Ventricle Size on Alzheimer¡¯s Disease Progression: A Retrospective Longitudinal Study
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Dementia Neurocog Dis.

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

Ä¡¸Å·Î Àüȯ½ÃŰ´Â À§ÇèÀÎÀÚ È®Àΰú Á¶Àý

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

Ä¡¸ÅÀÇ ´Ù¾çÇÑ Æ¯¼ºÀ» ¹àÈ÷°í, ¹ÙÀÌ¿À ¸¶Ä¿ ¿¬±¸¸¦ ÅëÇØ Á¶±â Áø´Ü°ú Ä¡·á¿¡ Àû¿ëÇϱâ À§ÇÑ ¿©·¯ À¶ÇÕ ¿¬±¸µéÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. Ä¡¸Å·Î Áø´ÜµÈ ½ÃÁ¡ºÎÅÍ ½ÃÀ۵Ǵ ¡®È¯Àڷμ­ÀÇ ¿©Á¤(Journey)¡¯À» ÇÔ²² ÇÒ °¡À̵åÀÌÀÚ µ¿¹ÝÀڷμ­ ¾à¹° 1Â÷ Ä¡·á¿Í ÇÔ²² ÃßÀû °üÂû, ÀÌÈÄ °Ç°­°ü¸®±îÁö Ä¡¸Å ȯÀÚº° ¸ÂÃãÇüÀ¸·Î Â÷º°È­µÈ Áø·á ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Ä¡¸Å ȯÀÚÀÇ Çʿ並 ÃæÁ·½Ãų ¼ö ÀÖµµ·Ï ÃÖ´ëÇÑ ³ë·ÂÇϰڽÀ´Ï´Ù!

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Ä¡¸Å´Â ¹Ýµå½Ã ¿¹¹æÇÏ°í °íÄ¥¼ö ÀÖ½À´Ï´Ù. ³ú°Ç°­À» À§ÇÏ¿© ¿­½ÉÈ÷ ³ë·ÂÇսôÙ.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

ÇѾç´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-2290-8114
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

ÇѾç´ëÇб³º´¿øÀº 1972³â °³¿ø ÀÌÈÄ, »ç¶ûÀÇ ½Çõ Á¤½ÅÀ» ¹ÙÅÁÀ¸·Î ÀÇ·áÀÇ ÇѰ迡 µµÀüÇϸç, Çõ½ÅÀûÀÎ ¼º°ú¸¦ ÀÌ·ï¿Ô½À´Ï´Ù. ·ù¸¶Æ¼½º ¹× ½Å°æ°èÁúȯ Ä¡·áÀÇ ¼±µµ º´¿ø°ú ÁßÁõ ¾ÏÁúȯ µî¿¡ ÃֽеðÁöÅÐ Çõ½Å ±â¼ú°ú ¿¬±¸Á߽ɺ´¿øÀ¸·Î¼­ AI, ºòµ¥ÀÌÅÍ µîÀ» Ȱ¿ëÇÑ ÀÓ»ó ¿¬±¸¸¦ °­È­ÇÏ¸ç ¹Ì·¡ ÀÇÇÐÀ» À̲ø°í ÀÖ½À´Ï´Ù.

ÇѾç´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼ºµ¿±¸ ¿Õ½Ê¸®·Î 222-1

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä